KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Outstanding for 6 consecutive years, with $77.2 million as the latest value for Q4 2014.

  • For the quarter ending Q4 2014, Shares Outstanding rose 21.12% year-over-year to $77.2 million, compared with a TTM value of $77.2 million through Dec 2014, up 21.12%, and an annual FY2014 reading of $77.2 million, up 21.12% over the prior year.
  • Shares Outstanding was $77.2 million for Q4 2014 at Alnylam Pharmaceuticals, up from $63.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $77.2 million in Q4 2014 and bottomed at $42.3 million in Q4 2010.
  • Average Shares Outstanding over 5 years is $55.7 million, with a median of $52.5 million recorded in 2012.
  • The sharpest move saw Shares Outstanding rose 0.89% in 2011, then grew 22.86% in 2012.
  • Year by year, Shares Outstanding stood at $42.3 million in 2010, then increased by 0.89% to $42.7 million in 2011, then increased by 22.86% to $52.5 million in 2012, then rose by 21.44% to $63.7 million in 2013, then rose by 21.12% to $77.2 million in 2014.
  • Business Quant data shows Shares Outstanding for ALNY at $77.2 million in Q4 2014, $63.7 million in Q4 2013, and $52.5 million in Q4 2012.